Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000007141
JPRN-UMIN000007141
Completed
Phase 2

Multicenter Phase II Clinical Study of the Safety and Efficacy of Discontinuing Nilotinib Treatment in Patients with Chronic Phase Chronic Myelogenous Leukemia Who Have Achieved Complete Molecular Response with Imatinib or Nilotinib - Stop Nilotinib trial (NILSt trial)

Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu0 sites120 target enrollmentFebruary 1, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic Myelogenenous Leukemia

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Chronic Myelogenenous Leukemia
Sponsor
Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu
Enrollment
120
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\) Patients previously treated by tyrosine kinase inhibitors other than imatinib or nilotinib. 2\) Patients confirmed to have the T315I point mutation of BCR\-ABL. 3\) Patients with a history of hematopoietic stem cell transplantation. 4\) Patients with cardiovascular dysfunction. 5\) Pregnant women or those with suspected pregnancy. Nursing women and those who plan to become pregnant during the study period.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
JPRN-jRCT2063230095Asou Hiroya21
Active, not recruiting
Phase 1
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 20.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-001923-38-DEKite Pharma, Inc16
Active, not recruiting
Phase 1
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.
EUCTR2018-001923-38-ITKITE PHARMA INC.108
Active, not recruiting
Phase 1
A Phase 1/2 Multicenter Study of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 20.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-001923-38-ESKite Pharma, Inc108
Active, not recruiting
Phase 1
A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.Relapsed/Refractory Chronic Lymphocytic LeukemiaMedDRA version: 21.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-001923-38-GBKite Pharma, Inc16